Latest Health News
Ukraine's Healthcare System Under Severe Strain as Attacks Surge 20% in 2025
Ukraine experienced its highest number of health care attacks in 2025, with a nearly 20% increase compared to 2024, bringing the total documented attacks since February 2022 to at least 2,881. WHO warns that after four years of war, mental health needs are staggering with 72% of Ukrainians experiencing anxiety or depression, while cardiovascular disease is surging with one in four experiencing dangerously high blood pressure
. To sustain operations and protect access to care for 700,000 people, WHO is appealing for US$42 million in funding for 2026
.
CAR-T Cell Immunotherapy Pioneers Awarded Prestigious Biology Prize
Carl June from the University of Pennsylvania and Michel Sadelain from Columbia University received the BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine for revolutionizing cancer treatment through CAR-T cell immunotherapy. The innovative approach involves extracting T cells from patients, genetically engineering them in the laboratory to recognize cancer cells, and reinfusing them to achieve disease remission
.
Universal Nasal Spray Vaccine Shows Promise Against Multiple Respiratory Threats
Researchers at Stanford Medicine developed an experimental universal vaccine delivered intranasally that shields against a broad range of respiratory viruses, bacteria, and allergens in mice studies. The vaccine, called GLA-3M-052-LS+OVA, works through a 'double whammy' mechanism that reduced viral levels in lungs by 700-fold and enables rapid adaptive immune responses in as little as three days
.
New Drug Delivery Platform Accelerates Development of Genetic Medicines
Scientists from the University of Nottingham's School of Pharmacy created an adaptable materials platform using modular building blocks that self-assemble with RNA to form nanoscale delivery particles. The platform demonstrated the ability to deliver RNA into diverse cell types with efficiency matching leading commercial transfection reagents, with successful testing reducing cancer-associated genes in breast tumor tissue and inducing protection against H1N1 influenza in mice
.
First-in-Class Drug Candidate Shows Promise for Multiple Myeloma Treatment
DTP3, an investigational drug developed by Professor Franzoso's team at Imperial College London, advanced to Phase 2 patient trials following positive Phase 1 results. The drug uses a novel mechanism of action by inhibiting an interaction between proteins GADD45β and MKK7, which most myelomas require for survival, and may also treat other cancers including diffuse large B-cell lymphoma
.
FDA Clears First Clinical Trial for Universal AAV Gene Therapy for Cancer
Siren Biotechnology announced that the FDA cleared its first Investigational New Drug application, enabling the initiation of the first-in-human clinical trial for its Universal AAV Immuno-Gene Therapy for cancer. With this clearance, Siren officially advanced to clinical-stage biotechnology company status
.
IL-12-Armored CAR-T Cells Show Improved Survival in Solid Tumor Models
Researchers introduced IL-12-expressing CAR-T cells targeting FOLR2 or TREM2 to deplete pro-tumor tumor-associated macrophages and reprogram the tumor microenvironment. Treatment with IL-12-armored anti-TAM CAR-T led to significantly improved survival in metastatic ovarian and lung cancer models
.
TREMFYA Demonstrates Sustained Remission in Ulcerative Colitis Through 3 Years
TREMFYA (guselkumab) long-term data show sustained clinical and endoscopic remission with histological improvements in ulcerative colitis through 3 years in the QUASAR trial. The results support the continued use of this immunotherapy for long-term management of inflammatory bowel disease
.
FDA Launches Accelerated Framework for Ultra-Rare Disease Therapies
The U.S. Food and Drug Administration launched a new framework designed to accelerate the development of individualized therapies for ultra-rare diseases. This initiative aims to streamline the regulatory pathway for treatments targeting extremely small patient populations
.
Cancer Vaccine Targeting KRAS Mutations Advances in Clinical Development
Researchers tested a pooled synthetic long peptide vaccine targeting six KRAS mutations combined with checkpoint inhibitors ipilimumab and nivolumab in resected pancreatic adenocarcinoma patients. Co-primary endpoints include safety and maximal percent change of IFNγ-producing mutant KRAS T cell responses within 17 weeks
.
AI Models Enhance Radiation Treatment and Cancer Patient Safety
Artificial intelligence models from Memorial Sloan Kettering Cancer Center are helping doctors improve radiation treatment and more accurately measure tumors while enhancing patient safety monitoring. These AI applications represent growing clinical integration of machine learning in oncology practice
.